Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02865811
Title Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Pegylated liposomal-doxorubicin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.